文献速递淋巴瘤

伯基特淋巴瘤:当前认识、未满足需求与研究方向

Burkitt lymphoma: current understanding, unmet needs, and research directions.
PubMed 文献 · Blood Adv · 2026-01-01

本文综述伯基特淋巴瘤(BL)的流行病学、分子生物学、诊断和治疗进展。基因组研究识别出跨传统分类的EBV阳性与阴性分子亚型;高收入国家强化化疗可高度治愈,而撒哈拉以南非洲生存率 rarely 超过50%。文章强调可扩展诊断工具与靶向治疗以缩小生存差距。

要点

  • EBV阳性与阴性BL分子亚型跨传统临床分类,具有不同生物学特征。
  • 高收入国家BL经强化多药化疗和抗体治疗高度可治愈。
  • 撒哈拉以南非洲BL生存率 rarely 超过50%,需可扩展诊断与分层治疗。

核心结论

  • 基因组学进展为BL早期检测、监测和低毒靶向治疗提供了新生物标志物和潜在靶点。
  • 缩小BL生存差距需在资源有限地区开发可扩展诊断工具和定制治疗策略。

研究设计与样本

  • 综述类文章,总结BL流行病学、分子生物学、诊断和治疗进展,并讨论未解问题与转化研究方向。

主要发现

  • EBV阳性与EBV阴性BL分子亚型跨越传统临床和流行病学分类,具有不同生物学特征。
  • 高收入国家BL经强化多药化疗和抗体治疗高度可治愈;撒哈拉以南非洲生存率 rarely 超过50%。
  • 生存差距反映诊断延迟、有效治疗可及性有限和支持治疗挑战。

临床怎么用

  • 在高收入国家,成人及复发难治BL仍是未满足需求重点人群。
  • 在资源有限地区,应优先开发可扩展诊断工具和定制治疗策略以缩小生存差距。

局限性

  • 需改进模型系统以研究治疗耐药并缩小生存差距。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Burkitt lymphoma (BL) is an aggressive B-cell lymphoma historically classified into endemic, sporadic, or immunodeficiency-associated BL based on clinical and epidemiological features. Recent genomic and epigenomic studies have refined this framework, distinguishing Epstein-Barr virus (EBV)-positive and EBV-negative BL molecular subtypes that cut across traditional clinical and epidemiological categories and exhibit distinct biological profiles. In high-income countries (HICs), BL is highly curable with intensive multiagent chemotherapy and antibody-based therapy. In contrast, survival in sub-Saharan Africa rarely exceeds 50%, reflecting diagnostic delays, limited access to effective treatment, and challenges in supportive care. This review summarizes the advances in BL epidemiology, molecular biology, diagnosis, and treatment, highlighting how genomic insights have identified novel biomarkers for earlier detection and monitoring, as well as potential targeted therapies with reduced toxicity. These advances present opportunities to develop scalable diagnostic tools and tailored therapeutic strategies to narrow survival disparities, particularly in resource-limited settings, where most patients occur, and among adults and patients with relapsed or refractory BL in HICs. We also outline key unanswered questions in BL epidemiology and pathogenesis, discuss opportunities for translational research, and emphasize the need for improved model systems to study therapeutic resistance to close the survival gap.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Khan A, López C, Turner SD, et al. Burkitt lymphoma: current understanding, unmet needs, and research directions. Blood Adv. 2026. PMID: 42448305. doi:10.1182/bloodadvances.2024015620

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。